Force J, et al. – The previous and recent therapeutic developments for metastatic melanoma patients underwent appraisal in this study. It was deduced that an improved comprehension of the optimal sequencing, combinations, and mechanisms underlying the development of resistance could present evidence for rational clinical trial designs of novel immunotherapy strategies in melanoma and other cancer subtypes.